Ketamine telehealth has been a wild ride these last few years. Every few months I give an update, and every time I do, things seem to change dramatically. For example, in just a few short weeks in February 2023, the situation went from “bad” to “good” (at least sort of) as it became clear that
A handful of entities are in various stages of the FDA approval process for MDMA and psilocybin drugs (see here and here for some of our prior analysis of the issues). FDA approval could happen in the next few years. But there’s a catch: psilocybin and MDMA are both schedule I drugs under the Controlled Substances Act (CSA).
At the kickoff of the Oregon legislative session in January, I wrote Oregon Psilocybin 2023: Legislative Forecast and Report. The session went awry in April, when Oregon Senate Republicans staged a walkout over gun and abortion bills. The walkout lasted six weeks, with our representatives re-opening for business on June 15th— just 10 days before sin die on
Anyone familiar with the cannabis industry knows how difficult it is to make money. Things are going to be even worse for people in the state-legal psychedelics industry – much worse. There are a few key reasons for this. I should note that this post is focused on the state-legal psychedelics industry (i.e., service centers)
Section 501(c)(3) of the Internal Revenue Code provides tax exemptions for qualifying charitable organizations, like religious groups. Naturally, religious groups that use psychedelics want 501(c)(3) status. But the Internal Revenue Service (IRS) – like many of its counterpart agencies – refuses to play ball. In 2021, a group called the Iowaska Church of Healing took the
The use of psilocybin (magic mushrooms) for therapeutic purposes gains traction Last month, the NBA and its players association reached a tentative deal that the league would no longer test players for marijuana. Indeed, the NBA is lifting its ban on marijuana in the new collective bargaining agreement. Meanwhile, the NFL and its players agreed
A few weeks ago, we held a webinar about ketamine regulation and the future of psychedelic medicine (for a recording, click here). At the time, there were big changes on the horizon for ketamine telehealth. In the last few weeks, there have been a few pretty significant developments that merit some attention. For some background,
Washington’s House and Senate have both approved the “Washington Psilocybin Services Act” (SB 5263) and the bill awaits Governor Jay Inslee’s signature. Psilocybin is a schedule I drug under the federal Controlled Substances Act and is the psychoactive or “hallucinogenic” component of magic mushrooms. Washington appears set to follow in the footsteps of Oregon and
The Oregon psilocybin program has a residency requirement. I explained how it works here, and wrote “queue the crazy business structures.” Because the program is off to a slow start (see here and here) I haven’t received as many crazy requests as expected. Well, that changed last week when I received a proposal that made
There are lots of psychedelics and psychedelic adjacent substances that are not scheduled under the Controlled Substances Act (CSA). Recently I wrote about amanita muscaria mushrooms and their legal status. Today, I want to talk about a different one: salvia divinorum. Salvia divinorum Salvia divinorum is a psychedelic substance. It was often used for religious
